| Therapy
|
<5 years
|
5–14 years
|
15+ years
|
| Cases
|
RRTooltip Adjusted relative risk (95% CITooltip confidence interval)
|
Cases
|
RRTooltip Adjusted relative risk (95% CITooltip confidence interval)
|
Cases
|
RRTooltip Adjusted relative risk (95% CITooltip confidence interval)
|
| Estrogen alone
|
1259
|
1.18 (1.10–1.26)
|
4869
|
1.33 (1.28–1.37)
|
2183
|
1.58 (1.51–1.67)
|
| By estrogen
|
|
|
|
|
|
|
| Conjugated estrogens
|
481
|
1.22 (1.09–1.35)
|
1910
|
1.32 (1.25–1.39)
|
1179
|
1.68 (1.57–1.80)
|
| Estradiol
|
346
|
1.20 (1.05–1.36)
|
1580
|
1.38 (1.30–1.46)
|
435
|
1.78 (1.58–1.99)
|
| Estropipate (estrone sulfate)
|
9
|
1.45 (0.67–3.15)
|
50
|
1.09 (0.79–1.51)
|
28
|
1.53 (1.01–2.33)
|
| Estriol
|
15
|
1.21 (0.68–2.14)
|
44
|
1.24 (0.89–1.73)
|
9
|
1.41 (0.67–2.93)
|
| Other estrogens
|
15
|
0.98 (0.46–2.09)
|
21
|
0.98 (0.58–1.66)
|
5
|
0.77 (0.27–2.21)
|
| By route
|
|
|
|
|
|
|
| Oral estrogens
|
–
|
–
|
3633
|
1.33 (1.27–1.38)
|
–
|
–
|
| Transdermal estrogens
|
–
|
–
|
919
|
1.35 (1.25–1.46)
|
–
|
–
|
| Vaginal estrogens
|
–
|
–
|
437
|
1.09 (0.97–1.23)
|
–
|
–
|
| Estrogen and progestogen
|
2419
|
1.58 (1.51–1.67)
|
8319
|
2.08 (2.02–2.15)
|
1424
|
2.51 (2.34–2.68)
|
| By progestogen
|
|
|
|
|
|
|
| (Levo)norgestrel
|
343
|
1.70 (1.49–1.94)
|
1735
|
2.12 (1.99–2.25)
|
219
|
2.69 (2.27–3.18)
|
| Norethisterone acetate
|
650
|
1.61 (1.46–1.77)
|
2642
|
2.20 (2.09–2.32)
|
420
|
2.97 (2.60–3.39)
|
| Medroxyprogesterone acetate
|
714
|
1.64 (1.50–1.79)
|
2012
|
2.07 (1.96–2.19)
|
411
|
2.71 (2.39–3.07)
|
| Dydrogesterone
|
65
|
1.21 (0.90–1.61)
|
162
|
1.41 (1.17–1.71)
|
26
|
2.23 (1.32–3.76)
|
| Progesterone
|
11
|
0.91 (0.47–1.78)
|
38
|
2.05 (1.38–3.06)
|
1
|
–
|
| Promegestone
|
12
|
1.68 (0.85–3.31)
|
19
|
2.06 (1.19–3.56)
|
0
|
–
|
| Nomegestrol acetate
|
8
|
1.60 (0.70–3.64)
|
14
|
1.38 (0.75–2.53)
|
0
|
–
|
| Other progestogens
|
12
|
1.70 (0.86–3.38)
|
19
|
1.79 (1.05–3.05)
|
0
|
–
|
| By progestogen frequency
|
|
|
|
|
|
|
| Continuous
|
–
|
–
|
3948
|
2.30 (2.21–2.40)
|
–
|
–
|
| Intermittent
|
–
|
–
|
3467
|
1.93 (1.84–2.01)
|
–
|
–
|
| Progestogen alone
|
98
|
1.37 (1.08–1.74)
|
107
|
1.39 (1.11–1.75)
|
30
|
2.10 (1.35–3.27)
|
| By progestogen
|
|
|
|
|
|
|
| Medroxyprogesterone acetate
|
28
|
1.68 (1.06–2.66)
|
18
|
1.16 (0.68–1.98)
|
7
|
3.42 (1.26–9.30)
|
| Norethisterone acetate
|
13
|
1.58 (0.77–3.24)
|
24
|
1.55 (0.88–2.74)
|
6
|
3.33 (0.81–13.8)
|
| Dydrogesterone
|
3
|
2.30 (0.49–10.9)
|
11
|
3.31 (1.39–7.84)
|
0
|
–
|
| Other progestogens
|
8
|
2.83 (1.04–7.68)
|
5
|
1.47 (0.47–4.56)
|
1
|
–
|
| Miscellaneous
|
|
|
|
|
|
|
| Tibolone
|
–
|
–
|
680
|
1.57 (1.43–1.72)
|
–
|
–
|
| Notes: Meta-analysis of worldwide epidemiological evidence on menopausal hormone therapy and breast cancer risk by the Collaborative Group on Hormonal Factors in Breast Cancer (CGHFBC). Fully adjusted relative risks for current versus never-users of menopausal hormone therapy. Source: [1]
|
Template documentation